Cardiac output (CO) is a key determinant of major organ blood flow and solute delivery to drug eliminating organs. As such, CO assessment is a key covariate in understanding altered drug handling in the critically ill. Newer minimally-invasive devices are providing unique platforms for such an application, although comparison data are currently lacking. In this study we evaluated the Vigileo ® (Edwards Lifesciences, Irvine, CA, USA) and USCOM ® (USCOM Ltd, Sydney, NSW) devices in 62 critically ill patients requiring antibacterial therapy. The mean CO Vigileo and CO USCOM for the first paired measurements were 8.20±2.65 l/minute and 6.84±2.57 l/minute respectively (P <0.001). A significant correlation was evident in all patients (r=0.537, P <0.001), although the recorded bias was large (1.36±2.51 l/minute, limits of agreement -3.6 to +6.3 l/minute). The overall percentage error was 65%. There was an improved correlation in those admitted with sepsis (r=0.639, P <0.001) compared to trauma (r=0.373, P=0.066), although bias, precision and percentage error were similar in both subgroups. In 54 patients a second paired assessment was obtained at three hours. A weak, although significant correlation (r=0.377, P=0.005) was observed suggesting that gross trends over time were similar. In conclusion, our findings demonstrate poor agreement between these techniques suggesting that these devices are not simply interchangeable when assessing CO in a research or clinical setting.
Cardiac output (CO) is a key measure of cardiovascular physiology, providing an index of myocardial function, and global oxygen, nutrient, and drug delivery to the tissues. As such, CO is utilised as an endpoint by many clinicians in the provision of fluid and vasoactive therapy 1 , although a role in potentially optimising drug dosing should also be appreciated. Specifically, CO is a major determinant of hepatic and renal blood flow 2 , which in turn can directly influence drug metabolism and excretion, depending on the relevant pharmacokinetics (PK) 3 . In scenarios where the rate of drug elimination is not limited by intrinsic organ function (e.g. saturable elimination pathways), increased major organ blood flow may potentially result in enhanced excretion through greater delivery of solute to drug eliminating tissues.
Prior research in critically ill postoperative patients has confirmed augmented creatinine clearances in correlation with an increased CO 4 , similar to changes encountered in normal pregnancy 5 . In the absence of organ dysfunction, increased CO may therefore promote enhanced drug elimination 6, 7 , predisposing to sub-therapeutic levels 8 . In the case of antibacterial therapy, this may promote either treatment failure or the selection of resistant strains 9 . Although the influence of altered physiology on antibacterial levels in sepsis is still under investigation, elevated CO has been documented in this setting 10 along with the requirement for timely and accurate antibacterial therapy to achieve clinical success. As such, the influence of changes in CO on antibacterial PK in the critically ill requires ongoing study.
Further emphasising this point, we have recently demonstrated a linear correlation between CO (using a minimally invasive pulse contour technique) and cefazolin clearance in patients undergoing elective or semi-elective open abdominal aortic aneurysm repair 11 . Although further validation is required in a critical care environment, this finding reinforces the impact of changes in CO on drug PK and suggests a perhaps previously under-appreciated role for beside assessment of CO in optimising antibacterial doses. this is also in the context of biochemical tests that are routinely used for such purposes, lacking sensitivity to accurately quantify altered organ function in the critically ill 12, 13 .
Complicating any such clinical application is ambiguity surrounding the most appropriate method of CO estimation in the critically ill 14 . Although pulmonary artery catheter (PAC) thermodilution techniques have traditionally been regarded as the 'gold standard', a variety of less invasive techniques have recently been developed 15 . these are attractive in a research setting as they require less skilled operators, are less costly and avoid the potentially significant complications associated with PAC insertion.
Two principal types of minimally invasive CO monitors are commonly used in clinical practice. The first group derive CO on the basis of arterial pulse waveform analysis, typically employing proprietary algorithms to determine beat-to-beat estimates of stroke volume and CO, with or without a requirement for external calibration. Currently three monitors are available for clinical use: Vigileo ® (Edwards Lifesciences, Irvine, CA, USA), PiCCO ® (PULSION Medical Systems, AG, Munich, Germany), and LiDCOrapid ® (LiDCO Ltd., London, UK).
the second group of monitors gaining popularity are those which employ ultrasound. Such devices include: the USCOM ® transthoracic Doppler CO monitor (USCOM Ltd, Sydney, NSW), and the CardioQ-ODM ® (Deltex Medical, West Sussex, UK) oesophageal Doppler monitor. These techniques typically measure blood-flow velocity either across the aortic valve, or in the descending aorta, following which CO is calculated by multiplying by the estimated cross-sectional area. Of note, USCOM has the principal advantages of being totally noninvasive, does not require the use of costly single-use consumables, and could conceivably be employed on a number of patients concurrently.
Despite the increasing popularity of minimally invasive CO monitoring, there is a significant lack of comparison data between devices leading to uncertainty regarding the utility of any one monitor for use in antibacterial PK studies or clinical dose modification. The aim of this investigation was therefore to examine whether USCOM could provide an accurate and re-usable alternative to Vigileo CO analysis (which has previously been employed in a perioperative environment 11 ), thereby simplifying future clinical or research work in this area.
MEtHODS

Study population
This investigation was performed in a 30-bed tertiary level intensive care unit, providing a range of organ support to critically ill patients. the only major patient groups not represented include: paediatrics, postoperative cardiothoracic patients and solid organ transplant recipients. Patients were enrolled prospectively as part of a larger study examining antibacterial dosing in at-risk patients 16 . As such, this represents a convenience sample of critically ill septic and traumatised patients admitted to this facility. The study protocol was approved by the institutional human research ethics committee (HREC 2007/188) and written informed consent was obtained from either the patient or their substitute decision maker.
Study protocol
this has previously been published in detail elsewhere 16 . In brief, Vigileo and USCOM measurements were obtained in all patients at the time of antibacterial dosing, and where possible again at three hours post dose. Analysis of USCOM data was performed by an investigator blinded to the arterial pulse contour CO results. Demographic and treatment data were recorded as part of the protocol.
The Vigileo system, employing second generation software (version 1.10), was connected to an existing intra-arterial catheter (sited in the radial artery) via a Flo trac ® (Edwards Lifesciences, Irvine, CA, USA) sensor. Age, gender, body weight and height were entered, following which the sensor was levelled to the phlebostatic axis, and zeroed to atmospheric pressure. Inspection of the arterial waveform was undertaken prior to CO measurement to ensure fidelity of the technique. The Vigileo monitor provides continuous CO data utilising the heart rate (HR), and an index of stroke volume (obtained from the arterial pressure waveform), which is automatically averaged and updated.
The USCOM device allows for beat-to-beat quantitative evaluations of 14 CO parameters, including CO, HR, stroke volume, stroke volume variability and systemic vascular resistance. the transducer is placed on the chest in either the left parasternal position to measure trans-pulmonary blood flow, or the suprasternal position to measure trans-aortic blood flow. The suprasternal position was used for all measurements in the study protocol. Demographic data (including age, height, weight and gender) were entered prior to measurement and used to calculate the aortic valve area.
The flow profile is displayed on the USCOM monitor with the spectral display showing variations of blood flow velocity with time. Algorithms are used to determine flow volumes from the raw Doppler data, independent of two-dimensional echocardiographic measurement of flow diameters. All research personnel received training in the technique prior commencement of the study, though all measurements were performed by the authors.
Statistics
Continuous data are presented as the mean (SD) or median [IQR] as appropriate. Categorical data are presented as counts (%). Correlation was assessed by means of a scatter graph and linear regression. Goodness of fit was determined by a Pearson (r) coefficient. Differences in mean values were assessed by a Paired Students t-test. Precision and bias were determined by a Bland-Altman plot 17 . The mean of the differences between the two measurements [=Σ(CO Vigileo -CO USCOM )/N] is referred to as the bias, whereas precision is the SD of the differences. Limits of agreement (LOA) is the range enclosed by ±1.96 SD. the percentage error was determined using the method described by Critchley and Critchley 18 . Differences in bias as a function of admission diagnosis, vasopressor requirement and gender were assessed by means of an independent Students t-test. A P value <0.05 was considered as statistical sig-nificance and all analyses were performed using SPSS (Chicago, IL, USA) and MedCalc for Windows (Belgium).
RESULtS
A total of 62 patients were enrolled in the study, all of whom had paired CO measurements obtained at the beginning of the dosing interval. Patients were categorised into two groups according to the primary admission diagnosis: trauma (n=25, 40.3%) and sepsis (n=37, 59.6%). Twentyone (33.9%) required vasopressors and 59 (95.2%) were mechanically ventilated on the day of the study. the principal demographic, physiological and anthropometric characteristics of the included patients are listed in table 1. the mean CO Vigileo and CO USCOM for the first paired CO measurements were 8.20±2.65 l/minute and 6.84±2.57 l/minute respectively (P <0.001).
Across all patients, a significant correlation was observed between the first Vigileo and USCOM CO measurements (r=0.537, P <0.001) ( Figure  1A) . The bias and precision between the two devices was 1.36±2.51 l/minute, with LOA of -3.6 to +6.3 l/minute (Figure 2A ). the overall percentage error was 65%. There was an improved correlation in those admitted with sepsis (r=0.639, P <0.001) ( Figure 1B) , although bias and precision were similar (1.25±2.17 l/minute), with LOA of -3.0 to +5.5 l/minute ( Figure 2B ) and the percentage error was 59%. In contrast, a much poorer correlation (r=0.373, P=0.066) was noted in patients admitted with trauma ( Figure 1C ). Bias ± precision was 1.53±2.98 l/minute in this group with LOA of -4.3 to +7.4 l/minute ( Figure 2C ) and a percentage error of 73%.
No significant difference in bias was demonstrated between diagnostic groups (P=0.667), or in those receiving vasopressor infusion (P=0.230). A lower bias was noted in women compared with men 0.39 (2.70) vs 1.90 (2.26) l/minute, P=0.023). this is likely to reflect the observation that women were under-represented in the trauma sub-group (n=4/25, 16%), and had a smaller body-surface area (1.81 vs 2.07 m 2 , P <0.001).
No significant correlation was demonstrated between age (P=0.636), fluid balance (P=0.296), and bias. However a weak positive correlation was noted with body surface area (BSA) (r=0.253, P=0.047) and a weak negative correlation was observed with HR (r=-0.286, P=0.024). this suggests that at increased heart rates USCOM will tend to report higher CO values than those recorded with Vigileo.
In 54 patients a second paired CO assessment was obtained at three hours post drug dosing. Figure 3 plots the change in CO between measurements for each device (ΔCO Vigileo vs ΔCO USCOM ). This demonstrates a weak, although significant, correlation (r=0.377, P=0.005) suggesting that gross trends in CO over time were similar with either device.
DISCUSSION
Recent data in a perioperative setting has suggested the potential utility of minimally in-vasive CO measurement in predicting renal drug clearance 11 . this current analysis has compared two bedside CO monitors in the context of a larger study examining antibacterial PK in critically ill patients 16 . Despite a significant correlation (particularly in the septic subgroup), Bland-Altman analysis demonstrates very poor agreement with percentage errors well outside acceptable margins 18 . In this respect, our findings clearly indicate that these devices are not simply interchangeable. Given our recent experience with Vigileo in patients undergoing open abdominal aortic aneurysm repair 11 , we would favour the application of this device where a PAC is not in situ for future research or clinical practice in this area.
To our knowledge, this is the first study comparing Vigileo and USCOM, although previous researchers have employed alternative Doppler based techniques. Concha et al compared transoesophageal echocardiography with Vigileo in patients undergoing laparoscopic surgery, reporting a bias ± SD of 1.17±1.6 l/minute and LOA of -2.02 to 4.37 19 . Similar investigation has been performed in patients undergoing abdominal aortic aneurysm surgery, with improved bias (0.12 l/minute) and LOA (-1.66 to 1.90 l/minute) 20 . Others have also reported comparable findings in perioperative patients receiving vasopressor and fluid therapy 21 .
More recently, McLean and colleagues compared Vigileo and transthoracic Doppler echocardiography in 53 critically ill patients manifesting shock 22 . Compared with our study, their reported percentage error was 49.3%, although improved agreement was demonstrated when patients manifesting atrial fibrillation and aortic stenosis were excluded (percentage error 29.5%) 22 .
The greater agreement between Vigileo and Dopper echocardiography, as compared to Vigileo and USCOM in our analysis, is likely related to the assumptions concerning aortic valve area. In this respect, Van den Oever and colleagues have previously evaluated USCOM in comparison with transoesophageal echocardiographic valve measurements in patients undergoing cardiac surgery 23 . Importantly, their findings demonstrated that USCOM calculated aortic and pulmonary valve areas did not correlate with measured values, suggesting this is a significant source of error. Of note, patients with known aortic valve disease were excluded from this analysis 23 .
Additional sources of error are likely to include difficulty in obtaining adequate acoustic windows, such as in the case of morbid obesity or distorted anatomy. Of interest, the larger bias in trauma- tised patients is likely to reflect this problem with limited positioning, dressings, and associated thoracic trauma complicating suprasternal Doppler CO assessment. The positive correlation between bias and BSA further highlights this issue. Overall, it must also be noted that USCOM has generally not performed favourably when compared to traditional PAC thermodilution techniques 24, 25 .
The ability of Vigileo to accurately measure CO in comparison to traditional methods is also uncertain 1 with a number of validation studies demonstrating mixed results 26 . In particular, initial studies raised concerns regarding the accuracy of the early software (v1.01) 27, 28 , although subsequent iterations appear to have improved the accuracy of the device 29 . Specifically, use of a wider casemix in development, and improved algorithms, appears to have enhanced its application.
Even with these improvements, accuracy of arterial pressure waveform analysis is still likely to be influenced by alterations in the pulse contour, such as in aortic stenosis and regurgitation 30, 31 . As a limitation in our analysis, we did not actively screen for such lesions. Similarly, periods of haemodynamic instability are also likely to lead to additional errors as has been demonstrated in previous studies 32 . Although this may help to explain the weak negative correlation observed between bias and HR, it is interesting to note that we did not identify any significant difference in bias associated with the use of vasopressors.
We have not employed traditional thermodilution CO measurements in this study, as PAC insertion was not available. In this respect, use of Vigileo measurements as the comparator in our analysis is based on the following: 1) in critically ill patients the reported percentage error in comparison to PAC thermodilution is 30% 26 (being the established threshold for acceptable agreement); 2) a concordance rate of 96% has been reported for trends (+/-30%) in CO when comparing Vigileo and PAC measurements in the critically ill 33 ; 3) PAC use is declining in modern intensive care practice 34 leading to unfamiliarity with the device, its insertion and results and; 4) for the purposes of antibacterial PK study the risk-benefit and economic considerations do not favour the use of more invasive techniques.
In conclusion, we have compared two minimally invasive CO monitors (Vigileo and USCOM) in the context of an antibacterial PK study in the critically ill. Our findings suggest poor agreement between the techniques, largely due to issues concerning the application of suprasternal Doppler CO assessment in critically ill patients.
